<DOC>
	<DOCNO>NCT02395601</DOCNO>
	<brief_summary>First human , open-label , sequential dose escalation expansion study CPI-1205 patient progressive B-cell lymphoma . CPI-1205 small molecule inhibitor EZH2 .</brief_summary>
	<brief_title>A Study Evaluating CPI-1205 Patients With B-Cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Adults ( age ≥ 18 year ) Histologically confirm diagnosis Bcell lymphoma progress spite prior treatment , additional effective standard therapy available Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Adequate hematological , renal , hepatic , coagulation laboratory assessment Must give write informed consent participate study performance studyrelated procedure A primary lymphoma central nervous system ( CNS ) know lymphomatous involvement CNS Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption CPI1205 , include unresolved nausea , vomit , diarrhea CTCAE grade &gt; 1 Treatment proton pump inhibitor , H2 antagonists , antacid Achlorhydria , either document suspected basis associate disease ( e.g. , pernicious anemia , atrophic gastritis , certain gastric surgical procedure ) Impaired cardiac function clinically significant cardiac disease , include follow : Acute myocardial infarction angina pectoris ≤ 6 month prior start study drug New York Heart Association Class III IV congestive heart failure QTcF &gt; 470 msec screen ECG Uncontrolled cardiac arrhythmia ( patient ratecontrolled atrial fibrillation exclude ) A past medical history clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , history labile hypertension history poor compliance antihypertensive regimen ) Any concurrent severe and/or uncontrolled concomitant medical condition could compromise participation study ( e.g. , clinically significant pulmonary disease , clinically significant neurological disorder , active uncontrolled infection ) Systemic anticancer treatment radiotherapy le 2 week first dose CPI 1205 Radioimmunotherapy ( e.g. , 131Itositumomab , 90Yibritumomab tiuxetan ) less 6 week first dose CPI1205 Treatment investigational small molecule le 2 week first dose CPI1205 . Treatment therapeutic antibody le 4 week first dose CPI1205 . Treatment medication strong inhibitor CYP3A4 Treatment medication inducer CYP3A4 enzymes Treatment medication know carry risk Torsades de Pointes Pregnant lactate woman Women child bear potential men reproductive potential , unwilling use adequate contraception study therapy 3 month thereafter Patients unwilling unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>EZH2 Inhibitor</keyword>
	<keyword>Phase 1</keyword>
</DOC>